Synopsys (SNPS) Valuation Check As Recent Returns Contrast With Long Term Performance

Simply Wall St

Synopsys (SNPS) shares recently closed at US$505.34, with returns mixed across different timeframes. This has left many investors asking whether the current level still reflects the company’s fundamentals in design automation and semiconductor IP.

See our latest analysis for Synopsys.

Recent trading has been choppy, with a 1 day share price return of 1.26% decline and a 7 day share price return of 2.76% decline. However, the 30 day and 90 day share price returns of 11.14% and 14.80% suggest momentum has been building again, even as the 1 year total shareholder return of 0.36% decline contrasts with the stronger 3 year and 5 year total shareholder returns of 50.55% and 84.82%.

If Synopsys has you thinking more broadly about software and chip design, this could be a good moment to look at other high growth tech and AI stocks that are shaping the next wave of automation.

With Synopsys trading at US$505.34, a price target around US$554 and an intrinsic value estimate suggesting a premium, the key question is simple: is there still a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 9.2% Undervalued

Compared with the last close at US$505.34, the most followed narrative points to a fair value of US$556.73, suggesting some upside in the modeled case.

The accelerating complexity and proliferation of AI, high-performance computing, and multi-die/chiplet-based architectures are increasing customer demand for Synopsys' advanced design, verification, and simulation solutions, solidifying its role as a mission-critical partner in next-generation chip and system development, supporting both revenue growth and opportunities for higher-margin recurring licensing.

Read the complete narrative.

Curious what kind of top line expansion, margin profile, and future earnings multiple have to line up to support that valuation gap and fair value? The narrative spells out a specific growth path, a step up in profitability, and an elevated earnings multiple that all need to work together. Want to see exactly which assumptions have the biggest impact on that US$556.73 figure?

Result: Fair Value of $556.73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still plenty that could unsettle this optimistic setup, including export restrictions affecting China and execution risk related to the Ansys integration and restructuring.

Find out about the key risks to this Synopsys narrative.

Another View: What The P/E Ratio Is Saying

That 9.2% undervalued fair value of US$556.73 sits awkwardly next to how the market is actually pricing Synopsys. At a P/E of 72.4x, the shares are far above the US Software industry on 31.8x and peers on 46.6x, while our fair ratio suggests 41.8x.

Put simply, the market is already paying a premium that is well beyond both the sector and the fair ratio the market could move towards. This points to valuation risk if expectations or sentiment cool. So which story do you trust more: the upbeat narrative or the rich multiple staring you in the face?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:SNPS P/E Ratio as at Jan 2026

Build Your Own Synopsys Narrative

If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view in just a few minutes with Do it your way.

A great starting point for your Synopsys research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Ready for more stock ideas worth your attention?

If Synopsys has sharpened your thinking, do not stop here. The right watchlist can start with just one fresh idea you have been overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Synopsys might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com